Blocking the early phases of infection may provide a window of opportunity that allows such interventions to inhibit HCMV gene expression and replication and modulate inflammatory and IFN host responses, thus hindering viral-induced immunopathogenesis. This evidence concerns the gene IFNA1 and infection.